Isoniazid
- PDF / 169,435 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 91 Downloads / 168 Views
1 S
Hepatotoxicity and psychosis: 2 case reports In a retrospective single-center study of 269 patients conducted between 2010 to 2018, 2 patients were described, of whom a patient [age and sex not stated] developed hepatotoxicity, and a 64-year-old man* developed psychosis during treatment with isoniazid for latent tuberculosis infection (LTBI) [routes, durations of treatments to reactions onset and outcomes not stated]. The patient, who had LTBI, started receiving treatment with isoniazid 300 mg/day along with pyridoxine. However, during the treatment with isoniazid, the patient developed adverse event in the form of hepatotoxicity associated with isoniazid. Subsequently, the treatment with isoniazid was permanently discontinued. The 64-year-old man, who had LTBI, started receiving treatment with isoniazid 300 mg/day along with pyridoxine. However, during the treatment with isoniazid, he developed adverse event in the form of psychosis associated with isoniazid. Subsequently, the treatment with isoniazid was permanently discontinued. * Identifying patient details (age and sex) have been obtained through direct communication with the author. Bettelli F, et al. Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center 803504766 study. Annals of Hematology 99: 2201-2203, No. 9, Sep 2020. Available from: URL: http://doi.org/10.1007/s00277-020-04191-3
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 3 Oct 2020 No. 1824
Data Loading...
